Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN: Depemokimab vs mepolizumab in relapsing or refractory EGPA
jRCT2031220070Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing depemokimab arm with mepolizumab arm (2 arms). Primary endpoint: Primary remission endpoint. Started Jul 2022; status: active, not recruiting.
02
Drugs
depemokimabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCT2031220070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220070.